This targeting approach, which is independent of an effect on hypertension, provides greater protection for the heart than kidneys during diabetes, suggesting that the pathological effects of myeloid MR signalling are more critical to the development of cardiac disease than kidney disease during diabetes. This evidence concerns the gene NR3C2 and diabetes mellitus.